Oklo Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Oklo Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.66M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($73.62M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($32.17M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.93M | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | ($1.06M) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($139.29M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($52.80M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($18.64M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($1.81M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.18M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.85M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $26.71M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $9.76M | Mar 24, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($82.17M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($38.39M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($16.00M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($954.7K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.88M) | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.21M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $352.0K | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $83.0K | Mar 24, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $281.74M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $14.89M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $510.14M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $504.72M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.25M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $30.88M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $49.25M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $19.40M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $17.90M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $250.86M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($34.36M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | ($3.08M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | ($13.18M) | Mar 29, 2024 |
| FY2021 | Feb 1, 2021 | $0 | Mar 31, 2022 |
| FY2022 | Jan 31, 2021 | $0 | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.62M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 17, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($240.77M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($135.11M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($61.49M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($13.80M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($13.19M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $788.45M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $97.13M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $9.87M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.58M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.34M | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 160.51M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 137.71M | Mar 17, 2026 |
| FY2024 | May 9, 2024 | 122.10M | Mar 24, 2025 |
| FY2024 | May 8, 2024 | 1.39M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | 69.24M | Mar 24, 2025 |